Guardion Health Sciences, Inc. (GHSI)
USD 3.22
(0.0%)
USD 3.22
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -6.35 Million USD | 40.29% |
| 2022 | -10.65 Million USD | -161.85% |
| 2021 | -4.06 Million USD | 49.68% |
| 2020 | -8.08 Million USD | 23.22% |
| 2019 | -10.52 Million USD | -1469.3% |
| 2018 | -670.94 Thousand USD | 85.74% |
| 2017 | -4.7 Million USD | -53206.39% |
| 2016 | 8859.00 USD | -98.83% |
| 2015 | 757.68 Thousand USD | -55.99% |
| 2014 | 1.72 Million USD | 66.91% |
| 2013 | 1.03 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -5.6 Million USD | 11.87% |
| 2024 Q2 | -14.82 Million USD | -164.46% |
| 2023 Q4 | -6.35 Million USD | 16.95% |
| 2023 Q2 | -8.36 Million USD | 4.66% |
| 2023 FY | -6.35 Million USD | 40.29% |
| 2023 Q3 | -7.65 Million USD | 8.47% |
| 2023 Q1 | -8.77 Million USD | 17.62% |
| 2022 Q2 | -4.2 Million USD | 12.52% |
| 2022 Q1 | -4.81 Million USD | -18.29% |
| 2022 FY | -10.65 Million USD | -161.85% |
| 2022 Q4 | -10.65 Million USD | 17.66% |
| 2022 Q3 | -12.93 Million USD | -207.32% |
| 2021 Q2 | -5.14 Million USD | 88.01% |
| 2021 Q3 | -3.24 Million USD | 36.86% |
| 2021 Q4 | -4.06 Million USD | -25.17% |
| 2021 Q1 | -42.93 Million USD | -431.11% |
| 2021 FY | -4.06 Million USD | 49.68% |
| 2020 Q2 | -11.09 Million USD | 10.12% |
| 2020 Q3 | -9.32 Million USD | 15.96% |
| 2020 Q4 | -8.08 Million USD | 13.28% |
| 2020 Q1 | -12.34 Million USD | -17.2% |
| 2020 FY | -8.08 Million USD | 23.22% |
| 2019 Q3 | -4.97 Million USD | -182.51% |
| 2019 FY | -10.52 Million USD | -1469.3% |
| 2019 Q4 | -10.52 Million USD | -111.49% |
| 2019 Q2 | -1.76 Million USD | -404.68% |
| 2019 Q1 | 578.4 Thousand USD | 186.21% |
| 2018 Q3 | -993.77 Thousand USD | 49.01% |
| 2018 Q4 | -670.94 Thousand USD | 32.48% |
| 2018 FY | -670.94 Thousand USD | 85.74% |
| 2018 Q1 | -3.06 Million USD | 34.93% |
| 2018 Q2 | -1.94 Million USD | 36.34% |
| 2017 Q2 | -126.41 Thousand USD | 53.92% |
| 2017 Q1 | -274.35 Thousand USD | -3196.9% |
| 2017 FY | -4.7 Million USD | -53206.39% |
| 2017 Q4 | -4.7 Million USD | -300.34% |
| 2017 Q3 | -1.17 Million USD | -829.66% |
| 2016 Q1 | 32.8 Thousand USD | -96.86% |
| 2016 FY | 8859.00 USD | -98.83% |
| 2016 Q4 | 8859.00 USD | -99.29% |
| 2016 Q3 | 1.24 Million USD | 1.88% |
| 2016 Q2 | 1.22 Million USD | 3636.22% |
| 2015 Q1 | 15.76 Thousand USD | -99.08% |
| 2015 Q4 | 1.04 Million USD | 36.86% |
| 2015 Q3 | 763.2 Thousand USD | 0.0% |
| 2015 FY | 757.68 Thousand USD | -55.99% |
| 2014 FY | 1.72 Million USD | 66.91% |
| 2014 Q4 | 1.72 Million USD | 0.0% |
| 2013 FY | 1.03 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | 445.309% |
| BioQuest Corp. | 177.38 Thousand USD | 3685.202% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | -32.107% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 189.008% |
| GSRX Industries Inc. | - USD | Infinity% |
| High Sierra Technologies, Inc. | 469.78 Thousand USD | 1453.73% |
| Instadose Pharma Corp. | - USD | Infinity% |